Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Tendera

Showing results (111-120 of 131) with videos related to

Pageof 14
Sort By:
Thrombosis and Haemostasis|August 9, 2012
Effects of intracoronary delivery of allogenic bone marrow-derived stem cells expressing heme oxygenase-1 on myocardial reperfusion injuryWojciech Wojakowski, Michal Tendera, Wieslaw Cybulski, et al.
European Heart Journal|August 25, 2009
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsMarco Metra, Eric Eichhorn, William T Abraham, et al.
European Heart Journal|April 9, 2024
Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Long-Term RegistryAlida L P Caforio, Juan P Kaski, Juan R Gimeno, et al.
ESC Heart Failure|October 23, 2020
Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomesJozef Bartunek, Andre Terzic, Beth A Davison, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 9, 2020
Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy RegistryJuan R Gimeno, Perry M Elliott, Luigi Tavazzi, et al.
Cardiology Journal|September 14, 2018
Effects of trans-endocardial delivery of bone marrow-derived CD133+ cells on angina and quality of life in patients with refractory angina: A sub-analysis of the REGENT-VSEL trialTomasz Jadczyk, Joanna Ciosek, Aleksandra Michalewska-Wludarczyk, et al.
ESC Heart Failure|August 9, 2020
ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patientsTiina Heliö, Perry Elliott, Juha W Koskenvuo, et al.
JACC. Cardiovascular Interventions|February 23, 2010
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)Gilles Montalescot, Stephen G Ellis, Mark A de Belder, et al.
American Heart Journal|October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionC Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
The Lancet. Diabetes & Endocrinology|September 18, 2017
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trialRury R Holman, Ruth L Coleman, Juliana C N Chan, et al.
Pageof 14

Showing results (111-120 of 131) with videos related to

Sort By:
Pageof 14
Thrombosis and Haemostasis|August 9, 2012
Effects of intracoronary delivery of allogenic bone marrow-derived stem cells expressing heme oxygenase-1 on myocardial reperfusion injuryWojciech Wojakowski, Michal Tendera, Wieslaw Cybulski, et al.
European Heart Journal|August 25, 2009
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trialsMarco Metra, Eric Eichhorn, William T Abraham, et al.
European Heart Journal|April 9, 2024
Endomyocardial biopsy: safety and prognostic utility in paediatric and adult myocarditis in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Long-Term RegistryAlida L P Caforio, Juan P Kaski, Juan R Gimeno, et al.
ESC Heart Failure|October 23, 2020
Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomesJozef Bartunek, Andre Terzic, Beth A Davison, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 9, 2020
Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy RegistryJuan R Gimeno, Perry M Elliott, Luigi Tavazzi, et al.
Cardiology Journal|September 14, 2018
Effects of trans-endocardial delivery of bone marrow-derived CD133+ cells on angina and quality of life in patients with refractory angina: A sub-analysis of the REGENT-VSEL trialTomasz Jadczyk, Joanna Ciosek, Aleksandra Michalewska-Wludarczyk, et al.
ESC Heart Failure|August 9, 2020
ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patientsTiina Heliö, Perry Elliott, Juha W Koskenvuo, et al.
JACC. Cardiovascular Interventions|February 23, 2010
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)Gilles Montalescot, Stephen G Ellis, Mark A de Belder, et al.
American Heart Journal|October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarctionC Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
The Lancet. Diabetes & Endocrinology|September 18, 2017
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trialRury R Holman, Ruth L Coleman, Juliana C N Chan, et al.
Pageof 14